Back to Results

An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination with Dual Checkpoint Blockade using Zalifrelimab (AGEN1884) and Balstilimab (AGEN2034) for Advanced or Metastatic Soft Tissue Sarcomas

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Breelyn Wilky,  MD

Breelyn Wilky, MD

Study ID

Protocol Number: 19-0554

More information available at ClinicalTrials.gov: NCT04028063

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers